PH12021552145A1 - Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy - Google Patents

Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Info

Publication number
PH12021552145A1
PH12021552145A1 PH1/2021/552145A PH12021552145A PH12021552145A1 PH 12021552145 A1 PH12021552145 A1 PH 12021552145A1 PH 12021552145 A PH12021552145 A PH 12021552145A PH 12021552145 A1 PH12021552145 A1 PH 12021552145A1
Authority
PH
Philippines
Prior art keywords
lnp
replicon rna
cancer immunotherapy
synthetic oncolytic
synthetic
Prior art date
Application number
PH1/2021/552145A
Other languages
English (en)
Inventor
Yizhou Dong
Darrell J Irvine
Yingzhong Li
Noor Momin
Ron Weiss
Karl Dane Wittrup
Original Assignee
Massachusetts Inst Technology
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Ohio State Innovation Foundation filed Critical Massachusetts Inst Technology
Publication of PH12021552145A1 publication Critical patent/PH12021552145A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH1/2021/552145A 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy PH12021552145A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (1)

Publication Number Publication Date
PH12021552145A1 true PH12021552145A1 (en) 2022-08-31

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552145A PH12021552145A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Country Status (14)

Country Link
US (2) US11717548B2 (en])
EP (1) EP3934673A1 (en])
JP (2) JP7561134B2 (en])
KR (1) KR20220006041A (en])
CN (1) CN113966221A (en])
AU (1) AU2020233788A1 (en])
BR (1) BR112021017637A8 (en])
CA (1) CA3132714A1 (en])
CO (1) CO2021013417A2 (en])
IL (1) IL285963A (en])
MX (1) MX2021010808A (en])
PH (1) PH12021552145A1 (en])
SG (1) SG11202109514VA (en])
WO (1) WO2020185293A1 (en])

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185293A1 (en) * 2019-03-08 2020-09-17 Massachusetts Institute Of Technology Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CZ310443B6 (cs) * 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US20250152737A1 (en) 2022-04-26 2025-05-15 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
AU2024208643A1 (en) * 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024211865A2 (en) * 2023-04-07 2024-10-10 Omega Therapeutics, Inc. Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
WO2025024704A1 (en) 2023-07-25 2025-01-30 Strand Therapeutics Inc. Polynucleotides comprising a micro rna detargeting sensor and uses thereof
CN119479778B (zh) * 2024-10-16 2025-04-25 北京悦康科创医药科技股份有限公司 一种lnp转染效率预测模型构建方法及装置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
HRP20161352T1 (hr) * 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
WO2014089061A1 (en) * 2012-12-03 2014-06-12 Yasuko Rikihisa Ehrlichial invasin for immunization, diagnosis, and cell delivery
WO2016037053A1 (en) * 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3212772A4 (en) * 2014-10-31 2018-10-03 Massachusetts Institute of Technology Delivery of biomolecules to immune cells
EP3297637B1 (en) 2015-05-21 2021-05-26 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
WO2020185293A1 (en) * 2019-03-08 2020-09-17 Massachusetts Institute Of Technology Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
EP4185274A1 (en) * 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
US20240140960A1 (en) * 2021-02-12 2024-05-02 Ohio State Innovation Foundation Sugar derived lipid nanomaterials and uses thereof
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Also Published As

Publication number Publication date
JP2022524391A (ja) 2022-05-02
US20240024394A1 (en) 2024-01-25
IL285963A (en) 2021-10-31
US12383589B2 (en) 2025-08-12
JP2025011109A (ja) 2025-01-23
BR112021017637A2 (en]) 2021-11-09
CA3132714A1 (en) 2020-09-17
JP7561134B2 (ja) 2024-10-03
EP3934673A1 (en) 2022-01-12
KR20220006041A (ko) 2022-01-14
US20200281994A1 (en) 2020-09-10
AU2020233788A1 (en) 2021-10-07
MX2021010808A (es) 2021-12-15
BR112021017637A8 (pt) 2022-08-16
US11717548B2 (en) 2023-08-08
CN113966221A (zh) 2022-01-21
WO2020185293A1 (en) 2020-09-17
CO2021013417A2 (es) 2022-01-17
SG11202109514VA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
PH12021552145A1 (en) Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
MX2025001503A (es) Medios y metodo para preparar vectores virales y usos de los mismos
EP4389889A3 (en) Compositions and methods for editing rna
MX2018008413A (es) Virus oncolitico modificado.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
WO2018109170A3 (en) Il-11ra antibodies
EP4465050A3 (en) Anti-tau antibodies and methods of use
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
EP4269441A3 (en) Il-15 and il-15ralpha sushi domain based on modulokines
EP4393546A3 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
BR112016023707A2 (pt) método para produzir l-aminoácidos com o uso de uma bactéria alcalifílica
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
WO2018169901A8 (en) Synthetic promoters
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2020260898A3 (en) Novel cancer antigens and methods
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof